Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tipranavir disodium
Drug ID BADD_D02227
Description Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Indications and Usage For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Marketing Status approved; investigational
ATC Code J05AE09
DrugBank ID DB00932
KEGG ID D03843
MeSH ID C107201
PubChem ID 163296
TTD Drug ID D0EV6T
NDC Product Code 0597-0003; 11014-0046; 12714-901
UNII 9BAN2XG1ZW
Synonyms tipranavir | tipranavir, (R-(R*,R*))-isomer | 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | Aptivus | tipranavir, (S-(R*,R*))-isomer | tipranavir, (S-(R*,S*))-isomer | tipranavir glucuronide | (2R)-3,6-Dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1R)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2H-pyran-4-yl beta-D-glucopyranosiduronic acid | tipranavir, (R-(R*,S*))-isomer | tipranavir C-14 | C14-tipranavir | 14C-tipranavir | tipranavir disodium | PNU-140690E | tipranavir sodium | PNU 140690 | PNU-140690
Chemical Information
Molecular Formula C31H31F3N2Na2O5S
CAS Registry Number 191150-83-1
SMILES CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)[N-]S(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)[O-])CC C4=CC=CC=C4.[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia17.15.03.002; 19.02.01.002--
Insulin resistance05.06.02.003; 14.06.02.003---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Lipase increased13.05.01.003--
Lipoatrophy14.08.04.006; 23.07.01.001--
Liver disorder09.01.08.001---
Liver function test abnormal13.03.04.030---
Lymphoma01.12.01.001; 16.20.01.001---
Malaise08.01.01.003--
Muscle haemorrhage12.01.07.016; 15.05.03.017; 24.07.01.037---
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myositis15.05.01.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001---
Nervous system disorder17.02.10.001---
Neuropathy peripheral17.09.03.003---
Neutropenia01.02.03.004---
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001---
Oesophageal candidiasis07.19.06.001; 11.03.03.008---
Opportunistic infection11.01.08.007---
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pneumonia11.01.09.003; 22.07.01.003---
Pneumonia streptococcal11.02.06.005; 22.07.06.006---
Pregnancy18.08.02.004---
Progressive multifocal leukoencephalopathy11.05.05.001; 17.16.02.002---
Prurigo23.03.04.017---
Pruritus23.03.12.001--
Rash23.03.13.001---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages